Safety and Effectiveness of TactiCath™ Contact Force, Sensor Enabled™ (TactiCath SE) Catheter for Ablation of Drug Refractory, Symptomatic, Persistent Atrial Fibrillation
A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 224 participants.
Also called NCT03650556
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 224 participants
- Sponsor
- Registry
-
NCT03650556
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia
- Registry status
- Completed
Technical summary
Registry record NCT03650556. Allocation not applicable; no masking; primary purpose treatment. Start 2018-09-28 (actual); primary completion 2020-12-21 (actual). Results posted on 2022-04-27.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Effectiveness of TactiCath™ Contact Force, Sensor Enabled™ (TactiCath SE) Catheter for Ablation of Drug Refractory, Symptomatic, Persistent Atrial Fibrillation
- Condition
- Persistent Atrial Fibrillation
- Intervention (Device)
- TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™
- Lead sponsor
- Abbott Medical Devices
Record details
- Record id
cardio:ct-nct03650556- Content hash
88378101d1919d493db8bc1ef6debf2cc00d8de9165052ec51e2e85ccd20008d